Login Preferences
About News Publications Statistics Downloads API Guide License How to use Preferences
bn:03457824n
Noun Concept
Categories: Monoclonal antibodies, Breakthrough therapy, Genentech brands, Novartis brands, Angiogenesis inhibitors
EN
ranibizumab  ATC code S01LA04  ATCvet code QS01LA04  Byooviz  Cimerli
EN
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. Wikipedia
Definitions
Relations
Sources
EN
Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment created from the same parent mouse antibody as bevacizumab. Wikipedia
Pharmaceutical drug Wikidata
IS A
compound
medicine
monoclonal antibody
biopharmaceutical
HAS PART
carbon
MEDICAL CONDITION TREATED
diabetic retinopathy
eye disease
glaucoma
macular edema
retinopathy
ROUTE OF ADMINISTRATION
intravitreal administration
SUBJECT HAS ROLE
angiogenesis inhibitor
Wikipedia
EN
ranibizumab
Wikidata
EN
Ranibizumab
Wikipedia Redirections
EN
ATC code S01LA04, ATCvet code QS01LA04, Byooviz, Cimerli, Lucentis, Ranibizumab-eqrn, Ranibizumab-nuna, Ranivisio, Susvimo, Ximluci
Wikidata Alias
EN
FAB-12 Variant Y0317, RFB002, RG-3645, Rhufab, rhuFab V2

Please note that, in order to improve your browsing experience on this website, BabelNet® uses various types of cookies, including: browsing functionality, performance and statistical cookies.

By continuing to browse the site you are agreeing to our use of cookies. OK

License